MLYS (Mineralys Therapeutics) Insider Ownership: 0.88 % (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLYS Mineralys Therapeutics Inc MLYS
33 GF Score
Price $26.12
! 3 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Insider Ownership?

Mineralys Therapeutics MLYS -3.51% 33 Insider Ownership is 0.88 % as of Aug. 13, 2026. GuruFocus rates MLYS with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mineralys Therapeutics's insider ownership is 0.88%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mineralys Therapeutics's Institutional Ownership is 104.09%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mineralys Therapeutics's Float Percentage Of Total Shares Outstanding is 83.53%.

Mineralys Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Insider Ownership Chart

Mineralys Therapeutics Historical Data

The historical data trend for Mineralys Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 1.65 1.62 1.37 1.31 0.96 0.90 1.19 1.06 0.90 0.88
MLYS
33GF Score
Mineralys Therapeutics Inc MLYS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.88 % mean?
Mineralys Therapeutics (MLYS) has a Insider Ownership of 0.88 % as of Aug. 13, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Insider Ownership too high?
Mineralys Therapeutics' current Insider Ownership is 0.88 %. Overall, Mineralys Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Insider Ownership compare to NKTR and PHVS?
Mineralys Therapeutics' Insider Ownership of 0.88 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Insider Ownership is 0.88 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Insider Ownership of 0.88 %. The current Insider Ownership is 0.88 %. Mineralys Therapeutics' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Insider Ownership is 0.88 % as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
33GF Score

Get the complete analysis for MLYS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.12
Price